Anvatabart opadotin
- Generic Name
- Anvatabart opadotin
- Drug Type
- Biotech
- CAS Number
- 2636710-07-9
- Unique Ingredient Identifier
- B2KH16FA7H
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
Not yet recruiting
- Conditions
- Upper Tract Urothelial Carcinoma
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06798246
ARX788 in HER2-positive Metastatic Breast Cancer Patients
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06663748
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT06578286
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast CancerHormone Receptor Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Laura Huppert, MD, BA
- Target Recruit Count
- 36
- Registration Number
- NCT06224673
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
The Rechallenge of ADCs in MBC Patients
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05571618
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Phase 2
Active, not recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Caigang Liu
- Target Recruit Count
- 136
- Registration Number
- NCT05426486
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Phase 2
Withdrawn
- Conditions
- HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ambrx, Inc.
- Registration Number
- NCT05041972
- Locations
- 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸AMR Kansas City, Kansas City, Missouri, United States
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT05018702
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ARX788 in Breast Cancer With Low Expression of HER2
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 54
- Registration Number
- NCT05018676
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT04829604
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath